Vδ2-T cells derived exosomes for tumor immunotherapy

Overview

The invention is about a potential therapeutic approach for cancers. The exosomes derived from Vδ2-T cellsnot only directly kill tumor cells but also indirectly inhibit tumor development and progression by enhancing T cell–mediated antitumor activities, which offers great possibility to overcome the shortcomings of conventional immunotherapies for tumors as a cell-free therapy.

Commercialisation opportunities

Licensing, collaboration and investment

Problem addressed

Current treatment options for EBV-associated cancers are very limited with remarkable unwanted off-target toxicities and incompletely effective for relapsed or refractory diseases. Novel cell-based immunotherapy may be able to inhibit tumor growth; however, could be seriously impeded due to the immunosuppressive tumor microenvironment, and may also create safety issues.

Innovation

Novel immunotherapeutic approach against tumors including solid tumors

Key impact

Compared with cell-based immunotherapy, exosomes are more stable in long term storage and can be a off-the-shelf product immediately administered into patients after thawed.
Better safety profile and resistant to acidic and immunosuppressive tumor microenvironment.
Dual antitumor activities (direct killing and inducing T cell immunity)

Application

Novel therapeutic for the treatment of cancers

Patent

PCT Application No. PCT/CN2020/112573

Website

The University of Hong Kong (HKU)

Founded in 1911, The University of Hong Kong (HKU) is the first and oldest institution of higher education in Hong Kong. For over a century, the University has dedicated itself to creating knowledge, providing education, and serving society. Today, HKU has an established worldwide reputation for being a research-led comprehensive University with ten Faculties and a strong commitment to intellectual freedom, liberty and diversity. HKU has a proud record of academic recognition in researches through honours and awards received from both local and international bodies.

Enquiry